Lenacapavir, a new HIV prevention drug, has proven to dramatically reduce the risk of infection according to data reported from the drugmaker Gilead Sciences, who found two annual injections of the drug reduced HIV infections by 96 percent.



1221879711

Twice-yearly injection reduced HIV infections by 96 percent, company says

The Hill

Washington

District of Columbia

United States

A drug currently used to treat HIV has also been found to dramatically reduce the risk of infection, significantly more than the primary option available for pre-exposure prophylaxis or PrEP.

Ad Fontes Media

All Sides

Media Bias/Fact Check

Warner Bros. Discovery

Atlanta

Fulton County

Georgia

Twice-a-year injection reduced risk of HIV infection by 96%, drug company says — more than daily PrEP pill

The data sets the stage for likely approval of Gilead's lenacapavir for HIV prevention.

CNBC

Roberts family

Gilead says its twice-yearly shot cut HIV infections by 96% in trial

Lenacapavir, a new HIV prevention drug, has proven to dramatically reduce the risk of infection according to data reported from the drugmaker Gilead Sciences, who found two annual injections of the drug reduced HIV infections by 96 percent. Data from the trial, known as PURPOSE 2, monitored cisgender men, transgender men, transgender women, and gender nonbinary…

Nexstar Media Group

Lencapavir, which is dosed only every six months, is highly effective at preventing HIV, but advocates worry its cost will blunt its impact.

NBC News

An injectable HIV-prevention drug is highly effective — but wildly expensive

By Deidre McPhillips, CNN (CNN) — A drug currently used to treat HIV has also been found to dramatically reduce the risk of infection, significantly more than the primary option available for pre-exposure prophylaxis or PrEP. In a Phase 3 clinical trial, 99.9% of participants who took a twice-a-year injection of lenacapavir for HIV prevention did not acquire an infection, according to data from drugmaker Gilead Sciences. There were only two case…

KEYT

News-Press & Gazette Company

(CNN) — A drug currently used to treat HIV has also been found to dramatically reduce the risk of infection, significantly more than the primary option available for pre-exposure prophylaxis or PrEP.

WAAY-TV

Entertainment Studios

Huntsville

Madison County

Alabama

Gilead says HIV prevention injection reduced cases by 96%, sending shares higher

Investing.com

Gilead says HIV prevention injection reduced cases by 96%, sending shares higher By Investing.com

HealthDay

Twice-Yearly Injection Cuts HIV Risk by 96%, But Will Cost Cut Access?

Gilead announced on Thursday that the twice-yearly use of lenacapavir, its injectable HIV capsule inhibitor, has been shown to be 96% effective in preventing this disease, which affects more than 39 million people worldwide.

Gilead ha anunciado este jueves que el uso dos veces al año de lenacapavir, su inhibidor inyectable de la cápsula del VIH, ha demostrado una eficacia del 96% en la prevención de esta enfermedad, que afecta a más de 39 millones de personas en todo el mundo.

Lenacapavir, dos veces al año: la fórmula que puede ayudar a acabar con la 'epidemia' de VIH

farodevigo.es

Lenacapavir, twice a year: the formula that can help end the HIV 'epidemic'

Gilead stock popped Thursday after the biotech giant said its twice-yearly shot prevented 99.9% of HIV infections in a study. The post Gilead Sciences Pops On A New $4 Billion Opportunity In HIV Prevention appeared first on Investor's Business Daily.

Twice-yearly injection reduced HIV infections by 96 percent, company says

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics